Role of Dutasteride in Treatment of Category IIIB Chronic Prostatitis (A Placebo Controlled Study)

Abstract

We aimed in this study to determine if Dutasteride can reduce symptoms in men with a clinical diagnosis of category IIIB chronic prostatitis (national institutes of health, NIH) compared with placebo. ⁃ A prospective randomized placebo controlled double blind study conducted in Urology Department Ain Shams University & Assuit General Hospital. The study included 50 patients were diagnosed with category IIIB chronic prostatitis. 1- Each patient had been assessed by NIH chronic prostatitis symptom index. 2- Each patient had been randomized to take either Dutasteride 0.5 mg once daily or placebo in a l:1 ratio. 3- The course of treatment had been 2 months. 4- After finishing the course of treatment each patient had been reassessed by NIH chronic prostatitis symptom index. In Dutasteride group the mean NIH chronic prostatitis symptom index in Dutasteride group was (27.62± 8.13 SD, 17.54 ± 7.76 SD before and after treatment respectively), and in placebo group it was (27.29 ± 6.45 SD, 16.83±7.41SD